Loading
A phase 3 trial of Belzutifan, Nivolumab, Lenvatinib and Cabozantinib in advanced solid tumours, run by Merck Sharp & Dohme LLC, now recruiting.
Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043) is a phase 3 interventional study registered as NCT07405164 by Merck Sharp & Dohme LLC, with 450 participants planned, started 2026-03-23 and due to reach its primary completion in 2034-01-14. Interventions recorded: Belzutifan, Nivolumab, Lenvatinib and Cabozantinib.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Belzutifan, Lenvatinib, Merck & Co. (MSD), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Belzutifan, Merck & Co. (MSD), Small-molecule kinase inhibitors and the tag pipeline.
Shares Belzutifan, Merck & Co. (MSD), Metastatic cancer (cancer that has spread), Small-molecule kinase inhibitors and the tag pipeline.
Shares Belzutifan, Lenvatinib, Merck & Co. (MSD) and the tag pipeline.
Shares Belzutifan, Lenvatinib, Merck & Co. (MSD) and the tag pipeline.
Shares Belzutifan, Lenvatinib, Merck & Co. (MSD), Small-molecule kinase inhibitors and the tag pipeline.
Shares Merck & Co. (MSD), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Merck & Co. (MSD), Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/